151 related articles for article (PubMed ID: 35845506)
1. Prognostic impact of high-risk factors and
Zhang Y; Wu Z; Zhang B; Hu H; Zhang J; Chen Y; Ding M; Cao Y; Deng Y
Ann Transl Med; 2022 Jun; 10(12):702. PubMed ID: 35845506
[TBL] [Abstract][Full Text] [Related]
2. The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study.
Liao L; Tang J; Hong Z; Jiang W; Li Y; Kong L; Han K; Hou Z; Zhang C; Zhou C; Zhang L; Sui Q; Xiao B; Mei W; Yu J; Yang W; Pan Z; Ding PR
BMC Cancer; 2024 Feb; 24(1):164. PubMed ID: 38302968
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
Sinicrope FA; Mahoney MR; Smyrk TC; Thibodeau SN; Warren RS; Bertagnolli MM; Nelson GD; Goldberg RM; Sargent DJ; Alberts SR
J Clin Oncol; 2013 Oct; 31(29):3664-72. PubMed ID: 24019539
[TBL] [Abstract][Full Text] [Related]
4. The relationship of KRAS expression with KRAS status, prognosis, and tumor-infiltrated T lymphocytes in colorectal cancer.
Zhou Y; Zeng Z; Li Z; Ruan L; Xie H; Ye F; Huang L; Liu H; Kang L
Therap Adv Gastroenterol; 2024; 17():17562848241249387. PubMed ID: 38757097
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
6. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
[TBL] [Abstract][Full Text] [Related]
7. Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer.
Hestetun KE; Rosenlund NB; Stanisavljević L; Dahl O; Myklebust MP
Front Oncol; 2022; 12():853545. PubMed ID: 36110945
[TBL] [Abstract][Full Text] [Related]
8. Deficient mismatch repair and
Zhang X; Ran W; Wu J; Li H; Liu H; Wang L; Xiao Y; Wang X; Li Y; Xing X
PeerJ; 2018; 6():e4341. PubMed ID: 29423347
[TBL] [Abstract][Full Text] [Related]
9. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer.
Guo TA; Wu YC; Tan C; Jin YT; Sheng WQ; Cai SJ; Liu FQ; Xu Y
Int J Cancer; 2019 Sep; 145(6):1625-1634. PubMed ID: 31162857
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
12. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.
Hutchins G; Southward K; Handley K; Magill L; Beaumont C; Stahlschmidt J; Richman S; Chambers P; Seymour M; Kerr D; Gray R; Quirke P
J Clin Oncol; 2011 Apr; 29(10):1261-70. PubMed ID: 21383284
[TBL] [Abstract][Full Text] [Related]
13. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.
Li W; Zhi W; Zou S; Qiu T; Ling Y; Shan L; Shi S; Ying J
PLoS One; 2015; 10(6):e0128202. PubMed ID: 26042813
[TBL] [Abstract][Full Text] [Related]
14. Serum Tumor Markers Combined With Clinicopathological Characteristics for Predicting MMR and KRAS Status in 2279 Chinese Colorectal Cancer Patients: A Retrospective Analysis.
Zhao N; Cao Y; Yang J; Li H; Wu K; Wang J; Peng T; Cai K
Front Oncol; 2021; 11():582244. PubMed ID: 34221952
[TBL] [Abstract][Full Text] [Related]
15. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
[TBL] [Abstract][Full Text] [Related]
16. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials.
Sinicrope FA; Foster NR; Yoon HH; Smyrk TC; Kim GP; Allegra CJ; Yothers G; Nikcevich DA; Sargent DJ
J Clin Oncol; 2012 Feb; 30(4):406-12. PubMed ID: 22203756
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of the relationship of DNA mismatch repair with clinicopathologic features and prognosis of colon cancer].
Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
Zhonghua Zhong Liu Za Zhi; 2015 Aug; 37(8):591-6. PubMed ID: 26714599
[TBL] [Abstract][Full Text] [Related]
18. [Correlation between mismatch repair proteins status and clinicopathological characteristics in sporadic colorectal cancer patients].
Xiao ZT; Zhang RX; Zhao Y; Peng JH; Lu SX; Zhang HZ; Ding PR; Wu XJ; Lu ZH; Li LR; Wan DS; Pan ZZ; Chen G
Zhonghua Yi Xue Za Zhi; 2017 Apr; 97(16):1248-1251. PubMed ID: 28441855
[No Abstract] [Full Text] [Related]
19. Deficient mismatch repair as a prognostic marker in stage II colon cancer patients.
Gkekas I; Novotny J; Fabian P; Nemecek R; Palmqvist R; Strigård K; Pecen L; Svoboda T; Gurlich R; Gunnarsson U
Eur J Surg Oncol; 2019 Oct; 45(10):1854-1861. PubMed ID: 31186203
[TBL] [Abstract][Full Text] [Related]
20. [Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients].
Liu Y; Zang FL; Qiu ZQ; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Liang H; Sun Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):440-448. PubMed ID: 34000774
[No Abstract] [Full Text] [Related]
[Next] [New Search]
